Drug news
Study 202 success for eteplirsen in Duchenne Muscular Dystrophy-Sarepta
Patients on Sarepta were able to walk 64.9 meters farther than the placebo group, stable results that Sarepta claims confirm the drug's benefits in this rare and fatal disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.